Vaccination against H5 HP influenza virus leads to persistent immune response in wild king penguins

Since 2021, the panzootic of high pathogenicity avian influenza (HPAI) represents an increasing threat to wild vertebrate populations. In this context, recent vaccines developed for poultry could provide tools for the conservation of wild endangered birds populations. The king penguin ( Aptenodytes patagonicus ), a long-lived seabird breeding in dense colonies with an extended chick-rearing period, was identified as a possible surrogate species for a vaccination trial in a sub-Antarctic natural setting. We investigate here the immune response of king penguin chicks to a self-amplifying mRNA vaccine against a H5 HPAI clade 2.3.4.4b protein. Thirty chicks were vaccinated (primo- and boost-injections), 20 were kept as controls. Along 250 days of monitoring, vaccinated chicks showed a high and persistent immune response, granting a strong seroneutralisation capacity against the virus, up to fledging. No adverse effects were observed. The screening for antibodies against unspecific avian influenza viruses suggested that no natural infection occurred over the entire trial. The emergence of HPAI in the Southern Indian Ocean in October 2024 highlights the timeliness of such experimental tests. Our results show the vaccine could provide a powerful tool for mitigation and emphasises the need for studies considering ethical and practical issues of vaccination for wildlife conservation.